Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
71M
-
Shares change
-
-5.55M
-
Total reported value, excl. options
-
$261M
-
Value change
-
-$21.7M
-
Put/Call ratio
-
1.85
-
Number of buys
-
68
-
Number of sells
-
-73
-
Price
-
$3.68
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q3 2024
172 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q3 2024.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71M shares
of 72.2M outstanding shares and own 98.28% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (14M shares), EVENTIDE ASSET MANAGEMENT, LLC (8.55M shares), FMR LLC (5.08M shares), BlackRock, Inc. (4.76M shares), VANGUARD GROUP INC (4.61M shares), Decheng Capital LLC (3.11M shares), CITADEL ADVISORS LLC (2.72M shares), MORGAN STANLEY (1.61M shares), Verition Fund Management LLC (1.5M shares), and PRIMECAP MANAGEMENT CO/CA/ (1.5M shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.